RCS - IXICO plc - Conference attendance - On Helix Digital

IXICOAnnouncement

08/07/2020 07:00

RNS Number : 3203S
  
IXICO plc
  
08 July 2020
  
 

IXICO plc
("IXICO" or the "Company")
 
Conference attendance 
On Helix Digital 13-14 July 2020
 
IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces the Company's digital attendance at the On Helix Digital conference, on the 13-14 July 2020.
 
On Helix is a conference organised by One Nucleus, a non-for-profit Life Sciences & Healthcare organisation supporting institutions, companies and individuals working in the sector and connecting them. The event intends to bring organisations and investors together to share insights and innovation to support R&D companies in their current and future therapeutics and technology developments.
 
IXICO will share a pre-recorded presentation by Robin Wolz, SVP Science & Innovation at IXICO plc, titled 'Biomarkers for CNS clinical trials from imaging and actigraphy.' Two AI approaches to measure biomarkers in CNS disorders will be presented; the first approach is a method based on deep learning to segment brain volume in Huntington's disease and the second novel approach is the sleep assessment in Parkinson's disease from wrist-worn actigraphy. There will be an opportunity to set up one-to-one tele-meetings with potential customers and investors.
 
To find out and more and to register please visit: http://www.onhelix.com/
 
The pre-recorded presentation will also be made available on the Company's website shortly after the event:
https://ixico.com/investors/company-information/investor-videos/
 
For further information please contact:
 



IXICO plc


+44 (0)20 3763 7498




Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer


 








 




Walbrook PR Ltd


Tel: 020 7933 8780 or IXICO@walbrookpr.com
 




Paul McManus / Lianne Cawthorne /


Mob: 07980 541 893 / 07584 391 303 /




Alice Woodings


07407 804 654









 
 
About IXICO (www.IXICO.com)
 
IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel imaging and digital biomarkers.
 
IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
NRAEAEXXEALEEAA